1
Inpharma 1439 - 29 May 2004 Off-label gabapentin sales are still soaring despite evidence of its ineffectiveness in some indications, reports the BMJ. Pfizer recently pleaded guilty to numerous charges for the illegal promotion of off-label use of the drug. The company has agreed to pay a criminal fine of $US240 million, plus $US152 million to healthcare programmes; the second largest fine issued in the industry. However, the settlement is only a minor setback for Pfizer with worldwide gabapentin [Neurontin] sales increasing from $US1.3 billion in 2000 to $US2.7 billion in 2003. Off-label indications accounted for > 90% of sales in 2003, according to whistleblower Dr David Franklin. Lenzer J. Pfizer pleads guilty, but drug sales continue to soar. BMJ 328: 1217, No. 7450, 22 May 2004 800973492 1 Inpharma 29 May 2004 No. 1439 1173-8324/10/1439-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Off-label gabapentin sales still soaring

  • View
    212

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Off-label gabapentin sales still soaring

Inpharma 1439 - 29 May 2004

■ Off-label gabapentin sales are still soaring despiteevidence of its ineffectiveness in some indications,reports the BMJ. Pfizer recently pleaded guilty tonumerous charges for the illegal promotion of off-labeluse of the drug. The company has agreed to pay acriminal fine of $US240 million, plus $US152 millionto healthcare programmes; the second largest fineissued in the industry. However, the settlement is onlya minor setback for Pfizer with worldwide gabapentin[Neurontin] sales increasing from $US1.3 billion in2000 to $US2.7 billion in 2003. Off-label indicationsaccounted for > 90% of sales in 2003, according towhistleblower Dr David Franklin.Lenzer J. Pfizer pleads guilty, but drug sales continue to soar. BMJ 328: 1217,No. 7450, 22 May 2004 800973492

1

Inpharma 29 May 2004 No. 14391173-8324/10/1439-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved